A similar observation has been reported in palbociclib (CDK4/6 inhibitor)-treated ER + BC cells [100] and in entinostat (histone deacetylase inhibitor)-treated in breast cancer cells, independent of ER status [95]. This evidence concerns the gene CDK4 and breast cancer.